New CAR-T therapy targets Hard-to-Treat brain cancer in early trial
NCT ID NCT07193628
Summary
This early-phase study tests a new treatment called EPC-003 for people with glioblastoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) designed to attack two targets on the cancer cells. About 14 participants will receive the therapy through a small device placed in the brain, with doses given weekly for six weeks. The main goal is to check safety and find the best dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.